


## SUPPLEMENTARY MATERIAL

**SM-Figure 1 Adjusted rates of amyloidosis in the spondyloarthritis (SpA) and non-SpA cohorts by sex.**

SpA\_amiloidosis

SM-Table 1: Clinical characteristics of the SpA and non-SpA cohorts

	SpA cohort	Non-SpA cohort	p	
	No. of admissions (%)	107,140 (100)	107,140(100)	
	Male %	66.63	66.63	0.998
	Age in years, mean (SD)	58.94 SD (15.58)	58.94 (15.58)	0.998
	Average length of stay in days, mean (SD)	10.59 SD (15.37)	7.89 (11.5)	<b>p&lt;0.001</b>
	Death (%)	3619 (3.37)	4388 (4.09)	<b>p&lt;0.001</b>
Charlson index and its components	Charlson index, mean (SD)	1.14 SD (1.81)	1.36 (2.12)	<b>p&lt;0.001</b>
	Severe liver disease (%)	1,479 (1.38)	1,928 (1.79)	<b>p&lt;0.001</b>
	Kidney disease (%)	8,347 (7.79)	5,708 (5.32)	<b>p&lt;0.001</b>
	Chronic obstructive pulmonary disease (%)	14,467 (13.5)	13,745 (12.82)	<b>p&lt;0.001</b>
	Connective tissue disease (%)	2,561 (2.39)	1,118 (1.04)	<b>p&lt;0.001</b>
	Pressure ulcer (%)	1,577 (1.47)	1,872 (1.74)	<b>p&lt;0.001</b>
	Dementia (%)	629 (0.58)	845 (0.78)	<b>p&lt;0.001</b>
	Metastases (%)	3,199 (2.98)	5,804 (5.41)	<b>p&lt;0.001</b>
	Acquired immunodeficiency syndrome (%)	771 (0.71)	872 (0.81)	<b>p=0.013</b>
	Diabetes mellitus (%)	14,856 (13.86)	14,677 (13.69)	p=0.265
	Tumour (%)	8,209 (7.66)	13,817 (12.89)	<b>p&lt;0.001</b>
	Leukaemia (%)	623 (0.58)	626 (0.58)	p=0.955
Lymphoma (%)	1,257 (1.17)	1,412 (1.31)	<b>p=0.003</b>	
CV Disease	Cardiovascular disease (%)	55,475 (51.77)	51,062 (47.65)	<b>p&lt;0.001</b>
	Ischemic heart disease (%)	11,718 (10.93)	12,246 (11.42)	<b>p&lt;0.001</b>
	Heart failure (%)	6,216 (5.80)	5,913 (5.51)	<b>p=0.005</b>
	Stroke (%)	4,730 (4.41)	5,822 (5.43)	<b>p&lt;0.001</b>
	Aortic aneurysm (%)	655 (0.61)	710 (0.66)	p=0.143
	Valvular disease (%)	3,545 (3.30)	3,047 (2.84)	<b>p&lt;0.001</b>
	Deep vein thrombosis/pulmonary embolism (%)	655 (0.61)	606 (0.56)	p=0.175
Others	Hypertension (%)	31,580 (29.48)	28,405 (26.51)	<b>p&lt;0.001</b>
	Smoking (%)	13,339 (12.45)	13,446 (12.54)	p=0.489
	Hyperlipidaemia (%)	17,847 (16.66)	17,236 (16.08)	<b>p&lt;0.001</b>
	Sarcoidosis (%)	133 (0.12)	87 (0.08)	<b>p=0.002</b>
	Cauda equina (%)	149 (0.13)	45 (0.04)	<b>p&lt;0.001</b>
	Uveitis (%)	554 (0.51)	33 (0.03)	<b>p&lt;0.001</b>
	Depression (%)	5,962 (5.56)	4,168 (3.89)	<b>p&lt;0.001</b>
Surgical Procedures	Hip prosthesis (%)	2,261 (2.11)	1,220 (1.13)	<b>p&lt;0.001</b>
	Knee prosthesis (%)	1,115 (1.04)	1,209 (1.12)	p=0.052
	Arthrodesis (%)	172 (0.16)	75 (0.07)	<b>p&lt;0.001</b>
	Upper limb prosthesis (%)	345 (0.32)	482 (0.44)	<b>p&lt;0.001</b>
	Axial skeleton surgery (%)	1,525 (1.42)	561 (0.52)	<b>p&lt;0.001</b>

## SpA\_amiloidosis

ID	ID (%)	19,151 (17.87)	10,323 (9.63)	<b>p&lt;0.001</b>
	Bacterial meningitis ID (%)	133 (0.12)	63 (0.05)	<b>p&lt;0.001</b>
	Heart ID (%)	453 (0.42)	62 (0.05)	<b>p&lt;0.001</b>
	Respiratory ID (%)	6,525 (6.09)	5,646 (5.26)	<b>p&lt;0.001</b>
	Kidney ID (%)	4,680 (4.36)	3,643 (3.4)	<b>p&lt;0.001</b>
	Skin ID (%)	1,726 (1.61)	1,117 (1.04)	<b>p&lt;0.001</b>
	Pyogenic arthritis (%)	411 (0.38)	76 (0.07)	<b>p&lt;0.001</b>
	Osteomyelitis (%)	446 (0.41)	119 (0.11)	<b>p&lt;0.001</b>
	Prosthesis ID (%)	446 (0.41)	173 (0.16)	<b>p&lt;0.001</b>
	Post-surgical ID (%)	1,244 (1.16)	1,186 (1.10)	p=0.237
	TB (%)	630 (0.61)	295 (0.27)	<b>p&lt;0.001</b>
	Pulmonary TB (%)	202 (0.19)	139 (0.13)	<b>p&lt;0.001</b>
	Centra nervous system TB (%)	17 (0.01)	6 (0.005)	<b>p&lt;0.001</b>
	Gastrointestinal TB (%)	13 (0.01)	0 (0)	<b>p&lt;0.001</b>
	Osteoarticular TB (%)	33 (0.03)	5 (0.004)	<b>p&lt;0.001</b>
	Spinal TB (%)	22 (0.021)	4 (0.003)	<b>p&lt;0.001</b>
	Urogenital TB (%)	7 (0.006)	6 (0.005)	p=0.455
	Miliary TB (%)	77 (0.07)	10 (0.009)	<b>p&lt;0.001</b>
	Cytomegalovirus (%)	109 (0.10)	77 (0.07)	<b>p=0.023</b>
	Epstein-Barr virus (%)	39 (0.03)	19 (0.01)	<b>p=0.012</b>
Herpes zoster (%)	258 (0.24)	154 (0.14)	<b>p=0.001</b>	
Hepatitis C virus (%)	1,418 (1.32)	1,644 (1.53)	<b>p&lt;0.001</b>	
Hepatitis B virus (%)	343 (0.32)	275 (0.25)	<b>p=0.007</b>	

Abbreviations: OR: odds ratio, SD: standard deviation; ID: infectious disease; TB: tuberculosis.

## SpA\_amiloidosis

**SM-Table 2:** Distribution of amyloidosis admissions by SpA type and sex.

			Gender		
			Men	Women	Total
SpA	AS	N admissions	381	73	454
		% within AS	83,9%	16,1%	100,0%
	PsA	N admissions	140	97	237
		% within PsA	59,1%	40,9%	100,0%
	SpA-IBD	N admissions	61	20	81
		% within SpA_IBD	75,3%	24,7%	100,0%
	ReA	N admissions	14	6	20
		% within ReA	70,0%	30,0%	100,0%
Total	N admissions		596	196	792
	% within SpA		75,3%	24,7%	100,0%

Abbreviations: SpA Spondyloarthritis; AS ankylosing spondylitis; PsA psoriatic arthritis; SpA-IBD spondyloarthritis-associated inflammatory bowel disease; ReA reactive arthritis;

SpA\_amioidosis

SM-Table 3. Linear trends in the incidence of amyloidosis in the SpA and non-SpA cohorts

	SpA cohort					Non-SpA cohort				
	Linear Trend	p-value	95% confidence interval		%/year	Linear Trend	p-value	95% confidence interval		%/year
<b>All</b>	0.954	0.000	0.934	0.973	<b>-4.630</b>	1.102	0.001	1.042	1.167	<b>10.250</b>
<b>Men</b>	0.944	0.000	0.923	0.965	<b>-5.635</b>	1.118	0.013	1.023	1.222	<b>11.840</b>
<b>Women</b>	0.981	0.373	0.942	1.023	<b>-1.859</b>	1.080	0.029	1.008	1.157	<b>7.992</b>